Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa

Biological Psychiatry

Volumn 49, Issue 7, 2001, Pages 644-652

  Kaye, Walter H ^a   Nagata, Toshihiko ^a,b   Weltzin, Theodore E ^a,c   Hsu, L K George ^a,d   Sokol, Mae S ^a,e   McConaha, Claire ^a   Plotnicov, Katherine H ^a   Weise, Jeff ^a   Deep, Dianne ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MENNINGER CLINIC   (United States)

Author keywords

Anorexia nervosa; Fluoxetine; Relapse prevention; SSRI

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANOREXIA NERVOSA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SYMPTOM; UNITED STATES; WEIGHT GAIN;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0035312564     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01013-1     Document Type: Article

References (64)

1. Dieting reduces plasma tryptophan and alters brain serotonin function in women
2. Does fluoxetine augment the inpatient treatment of anorexia nervosa?
3. Fluoxetine: A review of its pharmacodynamic and pharmocolinetic properties, and therapeutic efficacy in depressive illness
4. Amitriptyline in the treatment of anorexia nervosa: A double blind, placebo-controlled study
5. 2A promoter polymorphism and susceptibility to anorexia nervosa
6. Psychological correlates of weight gain in patients with anorexia nervosa
7. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa
8. Clomipramine and "drive" in people with anorexia nervosa
9. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletin of plasma tryptophan
10. Depression in anorexia nervosa
11. Replication of an association between 5-HT2A promoter polymorphism -1438G/A and anorexia nervosa, and association with obsessive-compulsive disorder
12. Are SSRI's effective in underweight anorexia nervosa?
13. Oestrogen and mental state
14. Manipulations of dietary tryptophan: Effects on mouse killing and brain serotonin in the rat
15. The Yale-Brown Obsessive Compulsive Scale (YBOCS): II. Validity
16. The Yale-Brown Obsessive Compulsive Scale (YBOCS): I. Development, use and reliability
17. Outcome of outpatient psychotherapy in a random allocation treatment study of anorexia nervosa
18. Fluoxetine
19. Fluoxetine treatment of anorexia nervosa: An open clinical trial
20. Brief psychotherapy in the treatment of anorexia nervosa: Outcome at one year
21. Anorexia nervosa: Treatment efficacy of cyproheptadine and amitriptyline
22. The assessment of anxiety states by rating
23. A rating scale for depression
24. The current status of treatment for anorexia nervosa and bulimia nervosa
25. Serotonin transporter gene-linked polymorphic region: Allele distributions in relationship to body weight and in anorexia nervosa
26. The outcome of anorexia nervosa: A reappraisal
27. Outcome of anorexia nervosa - A review of the literature (1954-1978)
28. Abnormalities in CNS monoamine metabolism in anorexia nervosa
29. Alterations in serotonin activity and psychiatric symptomatology after recovery from bulimia nervosa
30. CSF 5-HIAA concentrations in anorexia nervosa: Reduced values in underweight subjects normalize after weight gain
31. An open trial of fluoxetine in patients with anorexia nervosa
32. The genetic epidemiology of bulimia nervosa
33. Hunger, food intake and weight: The impact of clomipramine on refeeding anorexia nervosa population
34. Depression as a correlate of starvation in patients with eating disorders
35. A controlled family study of anorexia and bulimia nervosa: Psychiatric and effects of proband comorbidity
36. Hospitalization for anorexia nervosa
37. Oestradiol-17 Beta increases serotonin transporter (SERT) binding sites and SERT mRNA expression in discrete regions of female rat brain
38. Interaction of diet and drugs in the regulation of brain 5-hydroxy indoles and the response to painful electric shock
39. New weight standards for men and women
40. A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa
41. Mortality in eating disorders
42. Efficacy of drug treatment in obsessive-compulsive disorder: A meta-analytic review
43. Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa
44. An evaluation of family therapy in anorexia nervosa and bulimia nervosa
45. Effects of carbohydrate and protein meals on plasma large neutral amino acids, glucose and insulin plasma levels of anorectic patients
46. 5-HT2A promoter polymorphism in anorexia nervosa
47. Persistent perfectionism, symmetry, and exactness in anorexia nervosa after long-term recovery
48. Psychoneurotic characteristics of patients with anorexia nervosa before and after treatment and at 4-7 year follow-up
49. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls
50. Depression in the eating disorders: A review and analysis of descriptive, family, and biological findings
51. Mortality in anorexia nervosa
52. The Yale-Brown-Cornell eating disorder scale: A new scale to assess eating disorder symptomatology
53. Long-term prognosis of anorexia nervosa: A preliminary report
54. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa
55. Selective serotonin reuptake inhibitors
56. A pilot study of a randomized trial of cognitive analytical therapy vs educational behavioral therapy for adult anorexia nervosa
57. Neuroleptics in the short-term treatment of anorexia nervosa: A double-blind placebo-controlled study with sulpiride
58. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa
59. Pharmacotherapy of eating disorders
60. 5-HT2 receptor changes in major depression